| 摘要 |
<p>The invention concerns the treatment of insulin-resistant disorders. In particular, the invention concerns the treatment of insulin-resistant disorders by administration of IL-17, such as IL-17A and/or IL-17F antagonists, such as anti-IL-17A and/or IL-17F and/or IL-17Rc antibodies, or antibody fragments.</p> |
